Limits...
Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.

Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H - BMC Cancer (2009)

Bottom Line: The associations between clinicopathological factors and outcome were analyzed.Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.The results of the present study suggest that topoIIalpha expression is associated with histologically aggressive subtypes and shortened survival.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Otolaryngology, Hirosaki University School of Medicine, Hirosaki, Japan. marucell@hotmail.com

ABSTRACT

Background: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis. Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication. The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.

Methods: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors). The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma. The associations between clinicopathological factors and outcome were analyzed.

Results: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001). Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.

Conclusion: The results of the present study suggest that topoIIalpha expression is associated with histologically aggressive subtypes and shortened survival. Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma. Overall survival rate for: (A) total number of cases;(B) histological subtype of tumor comparing salivary duct carcinoma (SDC) and carcinoma ex pleomorphic adenoma (CaPA) with other types; and (C) each clinical stage.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2654461&req=5

Figure 1: Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma. Overall survival rate for: (A) total number of cases;(B) histological subtype of tumor comparing salivary duct carcinoma (SDC) and carcinoma ex pleomorphic adenoma (CaPA) with other types; and (C) each clinical stage.

Mentions: Of the 54 patients with salivary gland carcinomas, 37 (69%) were males and 17 (31%) were females. Their age ranged from 6 to 84 years (mean, 61.9 years); patients with mucoepidermoid carcinoma were the youngest (mean, 51.0 years), and patients with salivary duct carcinoma were the oldest (mean, 72.8 years). Most tumors were located in the parotid gland (65%, 35/54), followed by the minor salivary glands (22%, 12/54) and the submandibular gland (13%, 7/54). Of the 54 patients, 21 (39%) presented with stage I or II disease, and 33 (61%) presented with stage III or IV disease. In most cases, the primary treatment was surgical excision (85%, 46/54). The mean follow-up time for all 54 patients was 43 months (range, 6 to 133 months). The overall survival was 55% at 5 years (Fig. 1A). When the survival rate was compared by histologic type, univariate and multivariate survival analyses revealed that the group consisting of salivary duct carcinoma and carcinoma ex pleomorphic adenoma had the shortest survival, less than 3 years (Fig. 1B) (Table 2). In addition, the survival rate of patients with advanced clinical stages (stage III and IV) was significantly shorter than that of patients with stages I and II (p = 0.023) (Fig. 1C).


Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.

Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H - BMC Cancer (2009)

Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma. Overall survival rate for: (A) total number of cases;(B) histological subtype of tumor comparing salivary duct carcinoma (SDC) and carcinoma ex pleomorphic adenoma (CaPA) with other types; and (C) each clinical stage.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2654461&req=5

Figure 1: Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma. Overall survival rate for: (A) total number of cases;(B) histological subtype of tumor comparing salivary duct carcinoma (SDC) and carcinoma ex pleomorphic adenoma (CaPA) with other types; and (C) each clinical stage.
Mentions: Of the 54 patients with salivary gland carcinomas, 37 (69%) were males and 17 (31%) were females. Their age ranged from 6 to 84 years (mean, 61.9 years); patients with mucoepidermoid carcinoma were the youngest (mean, 51.0 years), and patients with salivary duct carcinoma were the oldest (mean, 72.8 years). Most tumors were located in the parotid gland (65%, 35/54), followed by the minor salivary glands (22%, 12/54) and the submandibular gland (13%, 7/54). Of the 54 patients, 21 (39%) presented with stage I or II disease, and 33 (61%) presented with stage III or IV disease. In most cases, the primary treatment was surgical excision (85%, 46/54). The mean follow-up time for all 54 patients was 43 months (range, 6 to 133 months). The overall survival was 55% at 5 years (Fig. 1A). When the survival rate was compared by histologic type, univariate and multivariate survival analyses revealed that the group consisting of salivary duct carcinoma and carcinoma ex pleomorphic adenoma had the shortest survival, less than 3 years (Fig. 1B) (Table 2). In addition, the survival rate of patients with advanced clinical stages (stage III and IV) was significantly shorter than that of patients with stages I and II (p = 0.023) (Fig. 1C).

Bottom Line: The associations between clinicopathological factors and outcome were analyzed.Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.The results of the present study suggest that topoIIalpha expression is associated with histologically aggressive subtypes and shortened survival.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Otolaryngology, Hirosaki University School of Medicine, Hirosaki, Japan. marucell@hotmail.com

ABSTRACT

Background: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis. Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication. The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.

Methods: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors). The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma. The associations between clinicopathological factors and outcome were analyzed.

Results: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001). Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.

Conclusion: The results of the present study suggest that topoIIalpha expression is associated with histologically aggressive subtypes and shortened survival. Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.

Show MeSH
Related in: MedlinePlus